IGF-1 LR3 1mg

IGF-1 LR3 1mg Research Peptide UK

IGF-1 LR3 1mg (Insulin-like Growth Factor 1 Long Arg3) is a synthetic 83-amino acid analogue of native IGF-1 (70 amino acids), incorporating an N-terminal 13-amino acid extension and an arginine substitution at position 3. Two structural modifications define the IGF-1 LR3 1mg research peptide: an arginine substitution at position 3, and a 13-amino acid N-terminal extension. These modifications dramatically reduce binding affinity for IGF-binding proteins (IGFBPs), extending the in vitro half-life from approximately 12 to 15 minutes for native IGF-1 to approximately 20 to 30 hours for IGF-1 LR3. Molecular weight approximately 9,117 Da.

IGF-1 LR3 acts as a selective agonist at the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase. Upon receptor binding, it initiates the downstream PI3K and Akt signalling cascade, governing cell survival and proliferation, alongside the MAPK and ERK cascade governing cell growth and differentiation. The extended IGFBP evasion means sustained receptor stimulation without repeated compound addition in long-duration cell culture assays — the primary advantage over native IGF-1 for laboratory use.

Researchers designing protocols with the IGF-1 LR3 research peptide should account for an important pharmacological caveat: IGF-1 LR3 1mg retains residual affinity for the insulin receptor (IR) and hybrid IR/IGF-1R receptors. Study designs investigating metabolic pathways must account for this variable and should not treat IGF-1 LR3 as a pure IGF-1R probe.

IGF-1 LR3 1mg is frequently incorporated into IGF-1 signalling, which has been studied in relation to upstream GH-axis pathways in experimental literature. Upstream GHRH and GHRP compounds — such as Ipamorelin 5mg targeting GHS-R1a and CJC-1295 Without DAC 10mg targeting GHRHR — stimulate GH secretion, which drives downstream IGF-1 production. IGF-1 LR3 1mg allows researchers to study the downstream growth factor component of the GH-IGF-1 axis in isolation, providing a mechanistically distinct probe from all upstream GH pathway compounds. For metabolic pathway research alongside IGF-1 axis work, AOD-9604 5mg targets the beta-3 adrenergic receptor pathway, providing a mechanistically non-overlapping metabolic research tool.

For complete mechanism, cell culture protocol guidance, and reconstitution guidance, see the IGF-1 LR3 1mg research guide on the Ascend Peptides UK blog.

All batches tested by Janoshik. HPLC greater than or equal to 98%. LC-MS confirmed at approximately 9,117 Da.

For laboratory handling purposes, IGF-1 LR3 may be reconstituted using acidic aqueous solutions such as dilute acetic acid or other suitable buffers depending on experimental requirements. Endotoxin levels should be assessed for cell culture applications.

WADA Status: Listed as a prohibited substance under anti-doping regulations at all times.

DISCLAIMER: For in-vitro research only. Not an MHRA-licensed medicine.